Literature DB >> 27654257

Dutch Risk Classification and FIGO 2000 for Gestational Trophoblastic Neoplasia Compared.

Yalcke Kjelle Eysbouts1, Leon Massuger, Chris Thomas, Petronella Ottevanger, Delia Short, Richard Harvey, Neil Sebire, Baljeet Kaur, Sarwar Naveed, Fred Sweep, Michael Seckl.   

Abstract

OBJECTIVE: Over the years, there has been a wide variety of classification systems in use worldwide to stratify patients between single-agent versus multi-agent chemotherapy, hindering comparison of international research results. The study presents a retrospective comparison of the International Federation of Gynecology and Obstetrics 2000 and Dutch risk classification system for gestational trophoblastic neoplasia. METHODS AND MATERIALS: All patients diagnosed with gestational trophoblastic neoplasia between January 2003 and December 2012 at the trophoblastic disease centre in London were retrospectively scored according to the Dutch classification system (N = 813).
RESULTS: An extensive overlap between both scoring systems was seen, even though items and relative value of items were quite distinct. The Dutch system seems to be simpler and easier to apply in all situation; a degree of overtreatment can however be presumed with the use of either system.
CONCLUSIONS: Although it is likely that outcome is indeed affected by the individual factors used in both systems, many factors relate to tumor bulk and may not be independently prognostic. We therefore believe that further refinement of the classification systems and their underlying prognostic items plus any new items that seem promising would be useful.

Entities:  

Mesh:

Year:  2016        PMID: 27654257     DOI: 10.1097/IGC.0000000000000812

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  2 in total

1.  Can the FIGO 2000 scoring system for gestational trophoblastic neoplasia be simplified? A new retrospective analysis from a nationwide dataset.

Authors:  Y K Eysbouts; P B Ottevanger; L F A G Massuger; J IntHout; D Short; R Harvey; B Kaur; N J Sebire; N Sarwar; F C G J Sweep; M J Seckl
Journal:  Ann Oncol       Date:  2017-08-01       Impact factor: 32.976

2.  Risk factors for second-line dactinomycin failure after methotrexate treatment for low-risk gestational trophoblastic neoplasia: a retrospective study.

Authors:  Y M Hoeijmakers; Fcgj Sweep; Car Lok; P B Ottevanger
Journal:  BJOG       Date:  2020-03-31       Impact factor: 6.531

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.